In April 2022, the US Food and Drug Administration (FDA) granted accelerated approval of this TKI for previously treated patients with advanced or metastatic cholangiocarcinoma (CCA) harboring FGFR2) fusions and other rearrangements based on results from the phase II FIGHT-202 trial (NCT02924376) [168]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.